Volume Alert - GILD 107.02 Gilead Sciences $GILD H
Post# of 162
Posted On: 11/11/2014 12:18:31 AM
Volume Alert - GILD 107.02 Gilead Sciences $GILD Hit a high today of 109.37 Closing the day 11/10/14 at 107.02 +0.57 +0.54% With a day low of 106.66 and a total volume of 21,953,805.
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 107.02 (+0.57), MRK: 58.81 (-0.53)
Jim Cramer's 'Mad Money' Recap: WWAV, GILD, BABA, AMZN
at The Street - Mon Nov 10, 7:38PM CST
Cramer says home gamers will never be able to beat the professional day traders but sticking with long-term themes can pay an annuity for many many years.
KMI: 38.50 (-0.25), AMZN: 305.11 (+5.25), GD: 140.82 (+0.68), LMT: 186.99 (+0.84), CLX: 101.67 (+0.88), RTN: 103.52 (-0.84), NOC: 135.65 (-0.46), DIS: 89.78 (-0.22), INTC: 33.26 (-0.32), WWAV: 36.00 (-0.93), GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), SSYS: 104.89 (+1.82), AAPL: 108.83 (-0.18), BABA: 119.15 (+4.59)
Final Glance: Biotechnology companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 107.02 (+0.57), AMGN: 163.09 (+2.84), CELG: 108.01 (+1.56)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 327.87 (+7.12), GILD: 107.02 (+0.57), SHPG: 200.98 (+2.40), ABBV: 63.79 (+2.29), CELG: 108.01 (+1.56)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.24 (-0.76), GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29)
Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74)
Stock Movers: Why These 5 Top Stocks Are Rising Today
at Investor's Business Daily - Mon Nov 10, 1:04PM CST
Here is why shares of biotech Gilead Sciences (GILD) and three four other highly rated stocks are rallying in heavy volume today. Gilead began running up in premarket trading after drug giant Merck (MRK) said Sunday it would not move forward with...
DHI: 23.43 (+0.30), AMBA: 49.21 (+2.07), GPRO: 75.75 (-3.31), HCA: 65.75 (unch), LEN: 45.29 (+0.75), YY: 82.43 (+2.93), GILD: 107.02 (+0.57), CYH: 48.12 (+0.31), MRK: 58.81 (-0.53), TASR: 18.93 (+0.41), TOL: 32.95 (+0.73), DGLY: 12.28 (+0.09)
Midday Glance: Biotechnology companies
AP - Mon Nov 10, 12:28PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 107.02 (+0.57), AMGN: 163.09 (+2.84), CELG: 108.01 (+1.56)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49)
Why Gilead Sciences Stock Is Still A Buy
Arie Goren - at Seeking Alpha - Mon Nov 10, 10:10AM CST
GILD: 107.02 (+0.57)
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $109.86
Comtex SmarTrend(R) - Mon Nov 10, 9:55AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $107.24 and have already reached the first level of resistance at $108.16. Analysts will be watching for a cross of the next upside pivot targets of $109.86 and $112.48.
GILD: 107.02 (+0.57)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29)
Early Glance: Biotechnology companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 107.02 (+0.57), AMGN: 163.09 (+2.84), CELG: 108.01 (+1.56)
Premarket: Stock Futures Mixed; Gilead Climbs On Merck News
at Investor's Business Daily - Mon Nov 10, 7:59AM CST
Stock futures shifted from thin, early losses to mixed trade ahead of Monday's open. Nasdaq 100 futures shed losses and were up a narrow 3.5 points. Dow futures remained 2.9 points below fair market value. S&P 500 futures were flat. The stock market...
WWAV: 36.00 (-0.93), GOGO: 18.40 (+1.76), GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), CMCM: 20.56 (+0.36), DF: 16.40 (+1.98)
Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power
PR Newswire - Mon Nov 10, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Genworth Financial (NYSE:GNW), Gilead Sciences (NASDAQ:GILD), Zynga (NASDAQ:ZNGA), Abercrombie & Fitch (NYSE:ANF), and Plug Power (NASDAQ
LUG).
GILD: 107.02 (+0.57), PLUG: 5.28 (-0.02), ANF: 28.69 (-0.81), ZNGA: 2.48 (+0.05), GNW: 8.12 (-0.29), BABA: 119.15 (+4.59)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
3 Drugs That Make Gilead Sciences' Harvoni Look Cheap
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 10, 6:31AM CST
Source: Bill Brooks/Flickr Healthcare costs are the leading cause of bankruptcy, so it's little wonder that people are up in arms over the cost of newly launched medicine like Gilead Sciences Harvoni. Gilead set the price of a 12-week...
GILD: 107.02 (+0.57), BMY: 58.81 (+0.49), NVS: 92.63 (+0.87)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 107.02 (+0.57), MRK: 58.81 (-0.53)
Jim Cramer's 'Mad Money' Recap: WWAV, GILD, BABA, AMZN
at The Street - Mon Nov 10, 7:38PM CST
Cramer says home gamers will never be able to beat the professional day traders but sticking with long-term themes can pay an annuity for many many years.
KMI: 38.50 (-0.25), AMZN: 305.11 (+5.25), GD: 140.82 (+0.68), LMT: 186.99 (+0.84), CLX: 101.67 (+0.88), RTN: 103.52 (-0.84), NOC: 135.65 (-0.46), DIS: 89.78 (-0.22), INTC: 33.26 (-0.32), WWAV: 36.00 (-0.93), GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), SSYS: 104.89 (+1.82), AAPL: 108.83 (-0.18), BABA: 119.15 (+4.59)
Final Glance: Biotechnology companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 107.02 (+0.57), AMGN: 163.09 (+2.84), CELG: 108.01 (+1.56)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 327.87 (+7.12), GILD: 107.02 (+0.57), SHPG: 200.98 (+2.40), ABBV: 63.79 (+2.29), CELG: 108.01 (+1.56)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.24 (-0.76), GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29)
Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74)
Stock Movers: Why These 5 Top Stocks Are Rising Today
at Investor's Business Daily - Mon Nov 10, 1:04PM CST
Here is why shares of biotech Gilead Sciences (GILD) and three four other highly rated stocks are rallying in heavy volume today. Gilead began running up in premarket trading after drug giant Merck (MRK) said Sunday it would not move forward with...
DHI: 23.43 (+0.30), AMBA: 49.21 (+2.07), GPRO: 75.75 (-3.31), HCA: 65.75 (unch), LEN: 45.29 (+0.75), YY: 82.43 (+2.93), GILD: 107.02 (+0.57), CYH: 48.12 (+0.31), MRK: 58.81 (-0.53), TASR: 18.93 (+0.41), TOL: 32.95 (+0.73), DGLY: 12.28 (+0.09)
Midday Glance: Biotechnology companies
AP - Mon Nov 10, 12:28PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 107.02 (+0.57), AMGN: 163.09 (+2.84), CELG: 108.01 (+1.56)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49)
Why Gilead Sciences Stock Is Still A Buy
Arie Goren - at Seeking Alpha - Mon Nov 10, 10:10AM CST
GILD: 107.02 (+0.57)
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $109.86
Comtex SmarTrend(R) - Mon Nov 10, 9:55AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $107.24 and have already reached the first level of resistance at $108.16. Analysts will be watching for a cross of the next upside pivot targets of $109.86 and $112.48.
GILD: 107.02 (+0.57)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29)
Early Glance: Biotechnology companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 107.02 (+0.57), AMGN: 163.09 (+2.84), CELG: 108.01 (+1.56)
Premarket: Stock Futures Mixed; Gilead Climbs On Merck News
at Investor's Business Daily - Mon Nov 10, 7:59AM CST
Stock futures shifted from thin, early losses to mixed trade ahead of Monday's open. Nasdaq 100 futures shed losses and were up a narrow 3.5 points. Dow futures remained 2.9 points below fair market value. S&P 500 futures were flat. The stock market...
WWAV: 36.00 (-0.93), GOGO: 18.40 (+1.76), GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), CMCM: 20.56 (+0.36), DF: 16.40 (+1.98)
Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power
PR Newswire - Mon Nov 10, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Genworth Financial (NYSE:GNW), Gilead Sciences (NASDAQ:GILD), Zynga (NASDAQ:ZNGA), Abercrombie & Fitch (NYSE:ANF), and Plug Power (NASDAQ
LUG). GILD: 107.02 (+0.57), PLUG: 5.28 (-0.02), ANF: 28.69 (-0.81), ZNGA: 2.48 (+0.05), GNW: 8.12 (-0.29), BABA: 119.15 (+4.59)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
3 Drugs That Make Gilead Sciences' Harvoni Look Cheap
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 10, 6:31AM CST
Source: Bill Brooks/Flickr Healthcare costs are the leading cause of bankruptcy, so it's little wonder that people are up in arms over the cost of newly launched medicine like Gilead Sciences Harvoni. Gilead set the price of a 12-week...
GILD: 107.02 (+0.57), BMY: 58.81 (+0.49), NVS: 92.63 (+0.87)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
(0)
(0)